Numbers

Claude View

The Numbers

Biocon trades at roughly ₹358 — essentially on top of GuruFocus' ₹355 fair value, but the tape tells a different story than the ratios. Revenue has tripled in five years on the back of the 2022 Viatris biosimilars acquisition, cash generation has inflected hard (FCF flipped from minus ₹748 cr in FY22 to plus ₹1,718 cr in FY25), and the GF Score sits at 89/100 with growth and profitability sub-ranks of 10 and 9. The single metric most likely to rerate this stock is net debt / EBITDA — now at 2.88x versus near-zero for every Indian pharma peer. If that leverage ratio keeps compressing toward 2.0x on the ₹4,500 cr June-2025 QIP plus accelerating biosimilars cash, multiple expansion follows. If it stalls, the trailing P/E of 81x looks a lot more fragile than the headline FY25 numbers suggest.

Snapshot

Price (₹)

358.1

Mkt Cap (₹ cr)

58,045

GF Score

GF Value (₹)

355.4

GF Value 12m (₹)

421.4

GF Score (0–100) blends financial strength, profitability, growth, momentum and GF-Value signals. GF Value is GuruFocus' fair-value estimate based on historical multiples, adjusted for business predictability. The 12-month GF Value of ₹421 implies roughly 18 percent upside from spot.

Quality scorecard — is this built to compound?

No Results

Strong everywhere it counts operationally (growth, profitability, predictability) — weak exactly where M&A has left a mark (balance sheet, momentum). The 4/10 balance-sheet rank is the one number on this card that bears watching. Piotroski F, Altman Z and Beneish M are not populated by GuruFocus for Indian listings.

Revenue & earnings power — 20 years

Gross margin has held above 65 percent for seven straight years — Biocon's specialty biosimilars and CRDMO mix is structurally high-margin. The telling gap is between gross and net: depreciation, interest (₹888 cr in FY25) and acquisition amortization have pulled net margin from 16 percent pre-Viatris to roughly 6.7 percent today. Operating leverage, not pricing, is the missing piece.

Quarterly momentum — last 16 quarters

Revenue is running at a roughly ₹16,500 cr annualized pace (Q4 FY25 annualized), but the top line has plateaued since the Viatris integration lapped its first full year. The story from here is margins, not growth velocity.

Segment mix

Biosimilars has gone from 38 percent of the mix to 58 percent in four years — the Viatris deal fundamentally changed what this company is. CRDMO (Syngene) and Generics together have grown at roughly half that pace.

Cash generation — are the earnings real?

FCF inflection is real: from six straight years of negative FCF (FY2016–FY2022) to **₹1,718 cr** in FY25. Capex has normalized around ₹2,300 cr while OCF has jumped 3.4x. This is the quiet story the P/E doesn't show.

Trailing 5-year OCF/NI averages roughly 3.0x — far above 1.0x and a clean signal that amortization of Viatris intangibles (above ₹1,000 cr annually) is suppressing reported earnings while the cash underneath keeps building.

Capital allocation — last 10 years

The ₹15,665 cr spike in FY23 is the Viatris Biologics acquisition — roughly 4x Biocon's then-revenue and financed almost entirely with debt. Capex stepped up to ₹2,343 cr in FY25 (about 15 percent of revenue), signalling capacity build-out to support the absorbed biosimilars pipeline. Dividends remain token; cash is being reinvested, not returned.

Balance sheet — leverage is the whole argument

Net debt / EBITDA peaked at 5.78x post-Viatris (FY23) and has since compressed to 2.88x as EBITDA doubled. The ₹4,500 cr QIP in June 2025 takes pro-forma leverage toward roughly 2.1x on FY26E EBITDA — the single biggest variable the equity story turns on. Drift beneath 2.0x is what unlocks a rerating.

Capital structure shift — promoter stake halved in nine months

**Promoter holding has dropped from 60.64 percent (Mar 2025) to 44.91 percent (Jan 2026)** — a 15.7 pp drop in three quarters. Two events drove this: the ₹4,500 cr QIP in June 2025 (roughly 6 pp dilution) and a further promoter sell-down in Jan 2026. DII holding has expanded from 15.7 percent to 24.1 percent over the same period — institutional absorption has been orderly, but the signal matters.

Valuation — now vs 20-year self

No Results

**The P/E lies; EV/EBITDA tells the truth.** Trailing P/E of 81x is optically stretched, but it is depressed by interest expense (₹888 cr FY25) and intangible amortization. EV/EBITDA of **16.8x** sits roughly in line with the 5y median (17.9x) and only modestly above the 20y median (13.9x). For an asset where EBITDA has doubled in three years, that is a neutral-to-supportive set-up.

Peer comparison — Indian pharma/biotech

No Results

Biocon has the highest EBITDA margin in the peer set (30 percent) yet the lowest ROCE and ROE by a wide margin — the anomaly is entirely a function of the Viatris-inflated capital base. Peers run near zero or net cash; Biocon carries 2.88x net debt. Re-leverage the denominator, and the returns story reads very differently.

Price — last 12 months

Stock ranged roughly ₹321–₹398 over the past year; current ₹358 sits near the middle. Street targets cluster ₹394–₹435.

Fair value scenario

No Results

Spread is ₹285 bear to ₹475 bull — roughly a 2:1 upside/downside ratio at ₹358. The bull case needs net debt / EBITDA to continue compressing toward 2.0x and biosimilars EBITDA margin to hold at 30 percent plus.

What the numbers confirm, contradict, and what to watch

The numbers confirm the biosimilars-led reinvention is working: revenue has tripled, EBITDA has doubled, cash conversion has gone from structurally broken to structurally strong, and a GF Score of 89 places Biocon in the top decile globally for business quality. They contradict the popular "value trap" framing — while optical P/E near 81x suggests nosebleed valuation, EV/EBITDA of 16.8x is essentially in line with Biocon's own 5-year history and the cash coming in the door has never been bigger. Watch: net debt / EBITDA — a drift beneath 2.0x by FY27 on continued EBITDA growth is what unlocks multiple expansion and validates the Viatris bet; a stall above 2.5x keeps the stock range-bound even if revenue grows.